Last reviewed · How we verify

CETRORELIX ACETATE

FDA-approved approved Recombinant protein Quality 28/100

Cetrorelix Acetate is a marketed drug primarily indicated for the inhibition of premature LH surges. Its key strength lies in its well-established mechanism and market presence, with a key composition patent expiring in 2028. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic nameCETRORELIX ACETATE
ModalityRecombinant protein
PhaseFDA-approved
First approval1999

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: